scholarly journals Therapeutic and Preventive Effects of a New Type Healthy and Viable Food Supplement on Fatty Liver and Blood Lipids in Animal Model

2020 ◽  
Author(s):  
Azam Bayat ◽  
Aref Khalkhali ◽  
Ali Reza Mahjoub
Keyword(s):  
Animal Model ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Blood Lipids ◽  
Food Supplement ◽  
Therapeutic Effects ◽  
Omega 3 ◽  
Calcium Iron ◽  
Preventive Effects

Abstract Background: Fatty liver disease is one of the most common liver complications worldwide. Also, blood lipids are elevated cholesterol or triglyceride levels from the normal amount in the blood that causes fatty liver disease. The aim of this study was to investigate the therapeutic effects of a new healthy and viable food supplement from wheat on fatty liver disease and blood lipids in animal model.Methods: The new NBS healthy and viable food supplement was prepared by a green route. The NBS healthy and live food powder had various vitamins, macro and micro molecules, and ingredients such as B1, B2, B3, B5, B6, B9, C, K, A, E, D, phosphorus, potassium, sulfur, magnesium, calcium, iron, manganese, zinc, copper, omega-3 and etc. For therapeutic and preventive effects of the new healthy and viable dietary supplement on fatty liver and blood lipids, 25 Wistar rats weighing 180–220 g were used. The rats were divided into 5 groups and were treated with 25, 50 and 100 mg/kg of healthy and live medication.Results: Investigation of the interaction between the concentrations of the medication supplement showed that 100 mg/ kg has the most therapeutic effect against oasises in fatty liver disease. Also, it was found that the concentration of 1000 mg/ kg has the most reducing effect on the level of lipid profile.Conclusions: The new food supplement reduces the level of hepatic macrovesicles, microvesicles, and the steatosis symptoms without specific hepatic complications. Also, the healthy food causes reduction of lipid parameters.

scholarly journals The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Aystematic Review and Network Meta-Analysis

2020 ◽  
Vol 10 (4) ◽  
pp. 542-555
Author(s):  
Ramin Jalili ◽  
Mohammad Hossein Somi ◽  
Hossein Hosseinifard ◽  
Fatemeh Salehnia ◽  
Morteza Ghojazadeh ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Therapeutic Effects ◽  
Omega 3 ◽  
Alcoholic Fatty Liver ◽  
Remarkable Effect ◽  
Increased Risk ◽  
Alcoholic Fatty Liver Disease

Purpose : Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis are two forms of fatty liver disease with benign and malignant nature, respectively. These two conditions can cause an increased risk of liver cirrhosis and hepatocellular carcinoma. Given the importance and high prevalence of NAFLD, it is necessary to investigate the results of different studies in related scope to provide a clarity guarantee of effectiveness. Therefore, this systematic review and metaanalysis aim to study the efficacy of various medications used in the treatment of NAFLD. Methods: A systematic search of medical databases identified 1963 articles. After exclusion of duplicated articles and those which did not meet our inclusion criteria, eta-analysis was performed on 84 articles. Serum levels of alanine aminotransferase (ALT), aspartate amino transferase (AST) were set as primary outcomes and body mass index (BMI), hepatic steatosis, and NAFLD activity score (NAS) were determined as secondary outcomes. Results: Based on the P-score of the therapeutic effects on the non-alcoholic steatohepatitis (NASH), we observed the highest efficacy for atorvastatin, tryptophan, orlistat, omega-3 and obeticholic acid for reduction of ALT, AST, BMI, steatosis and NAS respectively. Conclusion: This meta-analysis showed that atorvastatin. life-style modification, weight loss, and BMI reduction had a remarkable effect on NAFLD-patients by decreasing aminotransferases.

Omega-3 Fatty Acids and Fatty Liver Disease in Children

2018 ◽  
pp. 59-77 ◽  
Author(s):  
Claudia Della Corte ◽  
Salvatore Iasevoli ◽  
Andrea Dello Strologo ◽  
Mariateresa Sanseviero ◽  
Valerio Nobili
Keyword(s):  
Fatty Acids ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Omega 3 Fatty Acids ◽  
Omega 3

scholarly journals Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease

Nutrients ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3531
Author(s):  
Gigliola Alberti ◽  
Juan Cristóbal Gana ◽  
José L. Santos
Keyword(s):  
Oxidative Stress ◽  
Fatty Acids ◽  
Liver Disease ◽  
Vitamin E ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is currently the most common form of liver disease in both adults and children, becoming the leading cause for liver transplant in many countries. Its prevalence has increased considerably in recent years, mainly due to the explosive increase in pediatric obesity rates. NAFLD is strongly associated with central obesity, diabetes, dyslipidemia and insulin resistance, and it has been considered as the hepatic manifestation of the metabolic syndrome. Its complex pathophysiology involves a series of metabolic, inflammatory and oxidative stress processes, among others. Given the sharp increase in the prevalence of NAFLD and the lack of an appropriate pharmacological approach, it is crucial to consider the prevention/management of the disease based on lifestyle modifications such as the adoption of a healthy nutrition pattern. Herein, we review the literature and discuss the role of three key nutrients involved in pediatric NAFLD: fructose and its participation in metabolism, Omega-3 fatty acids and its anti-inflammatory effects and vitamin E and its action on oxidative stress.

The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease

2011 ◽  
Vol 30 (1) ◽  
pp. 6-19 ◽  
Author(s):  
Haim Shapiro ◽  
Miryam Tehilla ◽  
Joelle Attal-Singer ◽  
Rafael Bruck ◽  
Rachel Luzzatti ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Therapeutic Potential ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Nonalcoholic Fatty Liver ◽  
Long Chain

scholarly journals Murine models provide insight to the development of non-alcoholic fatty liver disease

2015 ◽  
Vol 28 (2) ◽  
pp. 133-142 ◽  
Author(s):  
D. T. Reid ◽  
B. Eksteen
Keyword(s):  
Animal Model ◽  
Liver Disease ◽  
Animal Models ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Treatment Strategies ◽  
Alcoholic Fatty Liver ◽  
Advantages And Disadvantages ◽  
The Metabolic Syndrome ◽  
Alcoholic Fatty Liver Disease

AbstractAssociated with the obesity epidemic, non-alcoholic fatty liver disease (NAFLD) has become the leading liver disease in North America. Approximately 30 % of patients with NAFLD may develop non-alcoholic steatohepatitis (NASH) that can lead to cirrhosis and hepatocellular carcinoma (HCC). Frequently animal models are used to help identify underlying factors contributing to NAFLD including insulin resistance, dysregulated lipid metabolism and mitochondrial stress. However, studying the inflammatory, progressive nature of NASH in the context of obesity has proven to be a challenge in mice. Although the development of effective treatment strategies for NAFLD and NASH is gaining momentum, the field is hindered by a lack of a concise animal model that reflects the development of liver disease during obesity and the metabolic syndrome. Therefore, selecting an animal model to study NAFLD or NASH must be done carefully to ensure the optimal application. The most widely used animal models have been reviewed highlighting their advantages and disadvantages to studying NAFLD and NASH specifically in the context of obesity.

Sign in / Sign up

Export Citation Format

Share Document